These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 36490241)

  • 1. Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.
    Kanbayashi Y; Shimizu M; Ishizuka Y; Sawa S; Yabe K; Uchida M
    PLoS One; 2022; 17(12):e0278823. PubMed ID: 36490241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for opioid-induced constipation in cancer patients: a single-institution, retrospective analysis.
    Kanbayashi Y; Ishizuka Y; Shimizu M; Sawa S; Yabe K; Uchida M
    Support Care Cancer; 2022 Jul; 30(7):5831-5836. PubMed ID: 35355120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.
    Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Obayashi K; Minato K
    Ann Palliat Med; 2023 Jul; 12(4):697-707. PubMed ID: 37081703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis.
    Kistemaker KRJ; Sijani F; Brinkman DJ; de Graeff A; Burchell GL; Steegers MAH; van Zuylen L
    Cancer Treat Rev; 2024 Apr; 125():102704. PubMed ID: 38452708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Naldemedine for Opioid-Induced Constipation in Children.
    Miura R; Utano T; Miura Y; Chiba K; Hasegawa A; Takafuji Y; Takahashi H; Tanzawa A; Iwahashi K; Yamatani A; Yotani N
    J Palliat Med; 2024 Oct; 27(10):1354-1358. PubMed ID: 39122251
    [No Abstract]   [Full Text] [Related]  

  • 6. A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer.
    Kamiya T; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984494
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study.
    Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
    Eur J Gastroenterol Hepatol; 2024 May; 36(5):571-577. PubMed ID: 38477855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting the effect of naldemedine for opioid-induced constipation: a single-institution, retrospective analysis.
    Kanbayashi Y; Amaya F; Ueno H; Tabuchi Y; Ishikawa T; Takayama K; Taguchi T
    Pharmazie; 2021 Apr; 76(4):175-178. PubMed ID: 33849704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
    Wild J; Webster L; Yamada T; Hale M
    Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and effectiveness of naldemedine for opioid-induced constipation in patients with advanced cancer in real-world palliative care settings: a multicenter prospective observational study.
    Shimizu M; Maeda I; Kessoku T; Ishiki H; Matsuura T; Hiratsuka Y; Matsuda Y; Hasegawa T; Imai K; Oyamada S; Satomi E;
    Support Care Cancer; 2024 Jul; 32(8):504. PubMed ID: 38985364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Naldemedine Administration for Opioid-Induced Constipation in Cancer Patients with Poor Performance Status.
    Fujita Y; Imai H; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
    J Palliat Med; 2023 Apr; 26(4):548-553. PubMed ID: 36971576
    [No Abstract]   [Full Text] [Related]  

  • 12. A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients.
    Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Kaira K; Minato K
    Thorac Cancer; 2022 Aug; 13(16):2301-2308. PubMed ID: 35790500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
    Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
    Song X; Wang D; Qu X; Dong N; Teng S
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
    Esmadi M; Ahmad D; Hewlett A
    J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
    Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naldemedine versus placebo in opioid-induced constipation: a meta-analysis.
    Wobbe B; Gerner M; Köhne CH
    BMJ Support Palliat Care; 2024 Jan; 13(e3):e578-e584. PubMed ID: 36517204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Survey of Prophylactic Administration of Naldemedine for Opioid-induced Constipation].
    Ozawa Y; Haruki Y; Ohata M; Isono H; Takahashi M; Tate A; Ukita S; Hayashi S
    Yakugaku Zasshi; 2023; 143(2):183-189. PubMed ID: 36724931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
    Takagi Y; Osawa G; Kato Y; Ikezawa E; Kobayashi C; Aruga E
    BMC Gastroenterol; 2020 Jan; 20(1):25. PubMed ID: 32005157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: A nationwide retrospective cohort study in Japan.
    Abe H; Sumitani M; Matsui H; Inoue R; Fushimi K; Uchida K; Yasunaga H
    Pharmacotherapy; 2022 Mar; 42(3):241-249. PubMed ID: 34967450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.